The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLV.c

Pleural thickening - Fibrothorax

Publications

Gefter WB, Epstein DM, Bonavita JA, Miller WT

Pleural thickening caused by Sansert and Ergotrate in the treatment of migraine.

AJR. American journal of roentgenology 1980 Aug;135;375-7 — 1980 Aug — 375-7

Graham JR, Suby HI, LeCompte PR, Sadowsky NL

Fibrotic disorders associated with methysergide therapy for headache.

The New England journal of medicine 1966 Feb 17;274;359-68 — 1966 Feb 17 — 359-68

Müller R, Weller P, Chemaissani A

[Pleural fibrosis as a side effect of years-long methysergide therapy].

Deutsche medizinische Wochenschrift (1946) 1991 Sep 20;116;1433-6 — 1991 Sep 20 — 1433-6